Baxalta
Baxalta is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Baxalta.
Baxalta is a company.
Key people at Baxalta.
Key people at Baxalta.
Baxalta Incorporated was a biopharmaceutical company focused on developing, manufacturing, and marketing therapies for rare and chronic conditions, including hemophilia, immunology, oncology, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiencies, burns, shock, and acute lymphoblastic leukemia[1][2][3]. It offered key products like ADVATE (recombinant factor VIII for hemophilia A), FEIBA (inhibitor management therapy), GAMMAGARD LIQUID (antibody-replacement for primary immunodeficiency), Hyqvia (immune globulin infusion for primary immunodeficiency), and Obizur (for acquired hemophilia A), serving patients with unmet medical needs in these areas[1][2]. Launched as a $6 billion independent entity in 2015 via spin-off from Baxter International, Baxalta emphasized sustainable supply, innovation through acquisitions, and expanding into gene therapy and oncology[2][3][4].
Baxalta originated as the biopharmaceutical division of Baxter International Inc., with Baxter announcing the separation in March 2014 to create two focused companies: one for biopharma (Baxalta) and one for medical products (retaining the Baxter name)[2][3][4]. Incorporated in Delaware on September 8, 2014, and headquartered in Bannockburn, Illinois, it became independent on July 1, 2015, through a pro rata distribution of 80.5% of its shares to Baxter shareholders, with Baxter retaining 19.5%[1][3]. Early milestones included 2010 licensing of Glassia for alpha-1 antitrypsin deficiency from Kamada Ltd., 2013 acquisition of hemophilia assets from Inspiration BioPharmaceuticals and Ipsen, and 2014 U.S. approval of Obizur[2]. Trading began on NYSE under BXLT on launch day, building on Baxter's legacy in recombinant therapies for hemophilia and rare blood disorders[3][4][5].
Baxalta rode the trend of biopharma spin-offs for focused innovation in rare diseases and biologics, capitalizing on growing demand for orphan drugs amid rising hemophilia and immunodeficiency prevalence[2][3][4]. Timing aligned with 2010s biotech boom, post-recombinant tech advancements, enabling niche expansion into gene therapy and oncology platforms amid favorable market forces like regulatory incentives for rare conditions[3][5]. It influenced the ecosystem by sustaining Baxter's hemophilia leadership, boosting supply for underserved patients, and modeling pure-play biopharma models that spurred sector M&A[2][4].
Post-2015 launch, Baxalta's trajectory shifted dramatically: Shire plc acquired it in 2016 for $32 billion, integrating its hemophilia and immunology assets into a larger rare disease powerhouse, with BXLT delisted[extrapolated from incorporation context; note: search results end at 2016 SEC filing]. Looking ahead from 2015 vantage, trends like gene therapy maturation and orphan drug pricing pressures would shape successors, evolving Baxalta's influence into broader Takeda (post-Shire acquisition) pipelines for sustained rare disease impact—reinforcing its role as a biopharma innovator from spin-off origins.
